- Home
- IDYA vs UVV Comparison
IDYA vs UVV Comparison
Compare IDYA & UVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- UVV
- Stock Information
- Founded
- IDYA 2015
- UVV 1886
- Country
- IDYA United States
- UVV United States
- Employees
- IDYA N/A
- UVV N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- UVV Farming/Seeds/Milling
- Sector
- IDYA Health Care
- UVV Industrials
- Exchange
- IDYA Nasdaq
- UVV Nasdaq
- Market Cap
- IDYA 1.5B
- UVV 1.3B
- IPO Year
- IDYA 2019
- UVV N/A
- Fundamental
- Price
- IDYA $21.22
- UVV $65.33
- Analyst Decision
- IDYA Strong Buy
- UVV
- Analyst Count
- IDYA 12
- UVV 0
- Target Price
- IDYA $54.27
- UVV N/A
- AVG Volume (30 Days)
- IDYA 1.5M
- UVV 221.0K
- Earning Date
- IDYA 05-06-2025
- UVV 05-29-2025
- Dividend Yield
- IDYA N/A
- UVV 5.02%
- EPS Growth
- IDYA N/A
- UVV N/A
- EPS
- IDYA N/A
- UVV 3.78
- Revenue
- IDYA $7,000,000.00
- UVV $2,947,284,000.00
- Revenue This Year
- IDYA $68.39
- UVV N/A
- Revenue Next Year
- IDYA $324.54
- UVV N/A
- P/E Ratio
- IDYA N/A
- UVV $17.30
- Revenue Growth
- IDYA N/A
- UVV 7.23
- 52 Week Low
- IDYA $13.45
- UVV $45.19
- 52 Week High
- IDYA $44.42
- UVV $67.33
- Technical
- Relative Strength Index (RSI)
- IDYA 65.40
- UVV 78.96
- Support Level
- IDYA $19.26
- UVV $58.68
- Resistance Level
- IDYA $20.46
- UVV $67.33
- Average True Range (ATR)
- IDYA 1.01
- UVV 1.69
- MACD
- IDYA 0.24
- UVV 0.65
- Stochastic Oscillator
- IDYA 99.55
- UVV 84.03
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About UVV Universal Corporation
Universal Corp is a global leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segment includes Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States.